Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting
Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Ghada Ahmed¹, Sandra L Goss¹, Cheri E Klein¹, Neelufar Mozaffarian², Gurjit S. Kaeley³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²Eli Lilly, San Diego, CA, ³College of Medicine, University of Florida, Jacksonville, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
Abstract Number: 1445 • 2013 ACR/ARHP Annual Meeting
GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis
Esme Roads¹, Scot Buchan² and Charles Li³, ¹Royal Surrey County Hospital, Guildford, United Kingdom, ²Strategen Ltd, Basingstoke, United Kingdom, ³Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom
Background/Purpose: Methotrexate (MTX) forms the backbone of treatment for the majority of patients with rheumatoid arthritis (RA), and is advocated in most guidelines.[i],[ii],[iii] Existing studies imply…
Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Kim Hørslev-Petersen¹, Lykke Midtbøll Ørnbjerg², Merete Lund Hetland³, Peter Junker⁴, Jan Pødenphant⁵, Torkell Ellingsen⁶, Palle Ahlqvist⁷, Hanne M. Lindegaard⁸, Asta Linauskas⁹, Annette Schlemmer¹⁰, Mette Y. Dam¹¹, Ib Hansen¹², Tine Lottenburger⁷, Anette Jørgensen¹³, Sophine B. Krintel¹⁴, Johnny Raun¹⁵, Christian G. Ammitzbøll¹¹, Julia Johansen¹⁴, Mikkel Østergaard¹⁶ and Kristian Stengaard-Pedersen¹¹, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴University of Southern Denmark, Odense, Denmark, ⁵Copenhagen University at Gentofte, Hellerup, Denmark, ⁶Silkeborg Regional Hospital, Silkeborg, Denmark, ⁷University of Southern Denmark, Vejle, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Vendsyssel Hospital, Hjørring, Denmark, ¹⁰Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹¹Arhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹³Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹⁴Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁵University of Southern Denmark, Graasten, Denmark, ¹⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…
Abstract Number: 1409 • 2013 ACR/ARHP Annual Meeting
Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Edward C. Keystone¹, Ferdinand C. Breedveld², Désiréé van der Heijde², Robert Landewe³, Stefan Florentinus⁴, Udayasankar Arulmani⁵, Shufang Liu⁵, Hartmut Kupper⁶ and Arthur Kavanaugh⁷, ¹University of Toronto, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Medical Center, Amsterdam, Netherlands, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷University of California San Diego, San Diego, CA
Background/Purpose: The PREMIER trial demonstrated the superiority of initial adalimumab (ADA)+MTX vs the individual monotherapies in MTX-naïve patients (pts) with early, aggressive rheumatoid arthritis (RA).…
Abstract Number: 1054 • 2013 ACR/ARHP Annual Meeting
Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang³, Lang Chen⁴, Huifeng Yun⁵, Michael H. Schiff⁶, Timothy Beukelman⁷ and Seth Ginsberg⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Creaky Joints, New York, NY
Background/Purpose: Methotrexate (MTX) is the most commonly used medication in rheumatoid arthritis (RA), although use of oral and subcutaneous (SQ) preparations in real-world settings has…
Abstract Number: 1037 • 2013 ACR/ARHP Annual Meeting
Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Atsushi Hashimoto¹, Noriyuki Chiba², Jinju Nishino³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory…
Abstract Number: 483 • 2013 ACR/ARHP Annual Meeting
Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
Sandra L Goss¹, Cheri E Klein¹, Hartmut Kupper², Gerd Burmester³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ³Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Higher exposure and lower immunogenicity rates have been observed for adalimumab when co-administered with methotrexate (MTX) compared to adalimumab monotherapy. The CONCERTO study was…
Abstract Number: 488 • 2013 ACR/ARHP Annual Meeting
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration
Walid Awni¹, Sabine Pilari², Ghada Ahmed³ and Peter Noertersheuser², ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ³AbbVie, North Chicago, IL
Background/Purpose: Co-administration of methotrexate (MTX) has a significant effect on the pharmacokinetics (PK) of adalimumab (ADAL). MTX may impact the PK of other drugs by…
Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Kim Hørslev-Petersen¹, Merete Lund Hetland², Peter Junker³, Jan Pødenphant⁴, Torkell Ellingsen⁵, Palle Ahlqvist⁶, Hanne M. Lindegaard⁷, Asta Linauskas⁸, Annette Schlemmer⁹, Mette Y. Dam¹⁰, Ib Hansen¹¹, Tine Lottenburger⁶, Anette Jørgensen¹², Sophine B. Krintel¹³, Johnny Raun¹⁴, Christian G. Ammitzbøll¹⁰, Julia Johansen¹³, Mikkel Østergaard¹⁵ and Kristian Stengaard-Pedersen¹⁰, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Copenhagen University at Gentofte, Hellerup, Denmark, ⁵Silkeborg Regional Hospital, Silkeborg, Denmark, ⁶University of Southern Denmark, Vejle, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Vendsyssel Hospital, Hjørring, Denmark, ⁹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Arhus University Hospital, Aarhus, Denmark, ¹¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹³Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁴University of Southern Denmark, Graasten, Denmark, ¹⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…
Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
P Durez¹, K Pavelka², M Lazaro³, A Garcia Kutzbach⁴, R Moots⁵, H Amital⁶, R Yao⁷, M Govoni^8,9, N Vastesaeger¹⁰ and HH Weng⁷, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Revmatologicky Ustav, Praha, Czech Republic, ³IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ⁴AGAR Francisco Marroquin University, Guatemala City, Guatemala, ⁵University Hospital Aintree, Liverpool, United Kingdom, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Rome, Italy, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…
Abstract Number: 2688 • 2013 ACR/ARHP Annual Meeting
Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity In Patients With Early Rheumatoid Arthritis Treated In Combination With Adalimumab – Results Of Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Ronald F. van Vollenhoven³, Stefan Florentinus⁴, Piyalal M. Karunaratne⁵, Hartmut Kupper⁶, Maxime Dougados⁷ and Roy Fleischmann⁸, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³The Karolinska Institute, Stockholm, Sweden, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Adalimumab is usually used in combination with 15-20 mg methotrexate (MTX) weekly in early rheumatoid arthritis (RA). Lower doses of MTX in combination with…
Abstract Number: 425 • 2013 ACR/ARHP Annual Meeting
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Hartmut Kupper³, Udayasankar Arulmani⁴, Stefan Florentinus⁵, Sandra Goss⁴, Suchitrita S. Rathmann⁴ and Roy Fleischmann⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses…
Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…
Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang¹, Lang Chen³, Huifeng Yun⁴, Michael H. Schiff⁵, David Mackey⁶ and Seth Ginsberg⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Division, University of Colorado, Denver, CO, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Creaky Joints, New York, NY
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].